Spironolactone May Benefit Some HF Patients

April 9, 2014 10:19 PM

94 0

Spironolactone May Benefit Some HF Patients

The TOPCAT trial of spironolactone for patients with heart failure and a preserved ejection fraction failed to meet its primary endpoint, but showed a modest reduction in heart failure hospitalizations with the drug, final results affirmed.

Through an average of 3.3 years of treatment, the rate of cardiovascular death, aborted cardiac arrest, or hospitalization for heart failure was 18.6% in the spironolactone group and 20.4% in the placebo group, a difference that did not reach statistical significance (HR 0.89, 95% CI 0.77-1.04), acc...

Read more

To category page